NRAS and melanoma: In a multi-institutional retrospective analysis of 229 melanoma patients, 60 patients (26%) had NRAS G12/G13/Q61 mutations, 53 patients (23%) had BRAFV600 mutations, and 116 (51%) had neither NRAS/BRAF mutations.